Dyne Therapeutics Croissance future

Future contrôle des critères 0/6

Dyne Therapeutics devrait augmenter ses bénéfices et son chiffre d'affaires de 8.2% et de 71.5% par an respectivement. Le BPA devrait croître de de 15.4% par an. Le rendement des capitaux propres devrait être -111.5% dans 3 ans.

Informations clés

8.2%

Taux de croissance des bénéfices

15.4%

Taux de croissance du BPA

Biotechs croissance des bénéfices	28.4%
Taux de croissance des recettes	71.5%
Rendement futur des capitaux propres	-111.5%
Couverture par les analystes	Good
Dernière mise à jour	20 Nov 2024

Mises à jour récentes de la croissance future

Recent updates

Companies Like Dyne Therapeutics (NASDAQ:DYN) Are In A Position To Invest In Growth

Aug 14

Dyne Therapeutics: Progress Undenied In DM1 And DMD Trials

May 21

We're Not Very Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

May 04

Dyne: H2 2024 Muscle Disease Data Could Boost Value

Mar 05

We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Dec 05

Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

Aug 09

We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Mar 26

We Think Dyne Therapeutics (NASDAQ:DYN) Needs To Drive Business Growth Carefully

Dec 10

Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Invest In Growth?

Aug 26

Dyne wins regulatory nod to start trial for myotonic dystrophy candidate

Jul 12

Dyne stock rises 12% as FDA lifts hold on starting muscle disorder study of DYNE-251

Jul 05

Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

May 05

We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely

Jan 12

We Think Dyne Therapeutics (NASDAQ:DYN) Can Afford To Drive Business Growth

Sep 29

Dyne Therapeutics' chief scientific officer Romesh Subramanian steps down

Jun 02

Here's Why We're Not Too Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

May 12

Dyne Therapeutics EPS beats by $0.10

May 06

Prévisions de croissance des bénéfices et des revenus

NasdaqGS:DYN - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	7	-455	-410	-389	6
12/31/2025	N/A	-409	-387	-356	9
12/31/2024	N/A	-326	-322	-278	9
9/30/2024	N/A	-295	-244	-243	N/A
6/30/2024	N/A	-258	-220	-219	N/A
3/31/2024	N/A	-257	-220	-220	N/A
12/31/2023	N/A	-236	-189	-188	N/A
9/30/2023	N/A	-208	-184	-182	N/A
6/30/2023	N/A	-189	-176	-175	N/A
3/31/2023	N/A	-177	-152	-150	N/A
12/31/2022	N/A	-168	-157	-154	N/A
9/30/2022	N/A	-181	-157	-153	N/A
6/30/2022	N/A	-182	-141	-137	N/A
3/31/2022	N/A	-160	-157	-152	N/A
12/31/2021	N/A	-149	-123	-120	N/A
9/30/2021	N/A	-126	-114	-112	N/A
6/30/2021	N/A	-97	-98	-96	N/A
3/31/2021	N/A	-77	-59	-58	N/A
12/31/2020	N/A	-59	-48	-47	N/A
9/30/2020	N/A	-36	-32	-30	N/A
6/30/2020	N/A	-28	-23	-22	N/A
3/31/2020	N/A	-21	-18	-17	N/A
12/31/2019	N/A	-15	-13	-12	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: DYN devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: DYN devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: DYN devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: DYN ne devrait pas générer de revenus l'année prochaine.

Croissance élevée des revenus: DYN ne devrait pas générer de revenus l'année prochaine.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: DYN devrait être non rentable dans 3 ans.

Dyne Therapeutics Croissance future

Future contrôle des critères 0/6

Informations clés

Mises à jour récentes de la croissance future

Price target increased by 8.9% to US$50.00

Price target increased by 8.3% to US$37.56

Price target increased by 9.6% to US$28.50

Price target decreased to US$24.67

Price target decreased to US$30.25

Recent updates

Dyne Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely

Dyne Therapeutics' Q3 Preview: High-Risk, High-Reward Path In Muscle Diseases

CEO, President & Director recently bought US$1.1m worth of stock

Dyne Therapeutics: Management Merry-Go-Round, Shaky Data Rock Wall Street

Dyne Therapeutics, Inc Announces Management Changes

Companies Like Dyne Therapeutics (NASDAQ:DYN) Are In A Position To Invest In Growth

Price target increased by 8.9% to US$50.00

Chief Operating Officer notifies of intention to sell stock

Dyne Therapeutics, Inc. Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress

Chief Operating Officer notifies of intention to sell stock

Dyne Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $325.5 million.

New major risk - Shareholder dilution

Chief Scientific Officer notifies of intention to sell stock

Dyne Therapeutics: Progress Undenied In DM1 And DMD Trials

Dyne Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

We're Not Very Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Dyne Therapeutics, Inc., Annual General Meeting, May 22, 2024

Dyne Therapeutics, Inc. Announces Chief Executive Officer Changes

CEO, President & Director recently sold US$223k worth of stock

Chief Operating Officer recently sold US$725k worth of stock

Price target increased by 8.3% to US$37.56

Dyne: H2 2024 Muscle Disease Data Could Boost Value

Dyne Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

CEO, President & Director notifies of intention to sell stock

Chief Business Officer exercised options and sold US$476k worth of stock

New major risk - Shareholder dilution

Dyne Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $300.125 million.

Dyne Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $300.125 million.

Dyne Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $175 million.

Chief Business Officer notifies of intention to sell stock

We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Chief Operating Officer notifies of intention to sell stock

New major risk - Financial position

CEO, President & Director notifies of intention to sell stock

Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

New major risk - Financial position

Insufficient new directors

CEO, President & Director recently sold US$618k worth of stock

CEO, President & Director notifies of intention to sell stock

Dyne Therapeutics, Inc. Announces Resignation of Dr. Lawrence Klein as Board Member

Insufficient new directors

We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Price target increased by 9.6% to US$28.50

Insider exercised options and sold US$133k worth of stock

Insider notifies of intention to sell stock

We Think Dyne Therapeutics (NASDAQ:DYN) Needs To Drive Business Growth Carefully

Dyne Therapeutics, Inc. Receives Fda Fast Track Designation for Dyne-251 for the Treatment of Duchenne Muscular Dystrophy

CEO, President & Director exercised options and sold US$2.4m worth of stock

Dyne Therapeutics, Inc. Presents Preclinical Data from Its Duchenne Muscular Dystrophy Programs Targeting Exons 51 and 53 At World Muscle Society 2022 Congress

Dyne Therapeutics, Inc. Prioritizes its Focus and Resources on its Clinical Programs, DYNE-101 in DM1 and DYNE-251 in DMD

Dyne Therapeutics Announces Initiation of Phase 1/2 ACHIEVE Clinical Trial of DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

Dyne Therapeutics, Inc. Appoints Francesco Bibbiani as Senior Vice President, Head of Development

Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Invest In Growth?

Dyne Therapeutics, Inc. Announces “Breakthrough Article” Publication of Duchenne Muscular Dystrophy Program Data in Nucleic Acids Research

High number of new directors

Price target decreased to US$24.67

Dyne Therapeutics Announces Clearance of Clinical Trial Application for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

Dyne wins regulatory nod to start trial for myotonic dystrophy candidate

Dyne Therapeutics, Inc. Announces FDA Clearance of IND Application for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy

Dyne stock rises 12% as FDA lifts hold on starting muscle disorder study of DYNE-251

Dyne Therapeutics, Inc. Presents New In Vivo Data from DYNE-101

Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

High number of new directors

Dyne Therapeutics, Inc., Annual General Meeting, Jun 03, 2022

Price target decreased to US$30.25

Dyne Therapeutics, Inc. Appoints Carlo Inert, M.D., to Its Board of Directors

Dyne Therapeutics Announces FDA Clinical Hold on IND Application for DYNE-251 in Duchenne Muscular Dystrophy

We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely

Dyne Therapeutics, Inc. Announces Submission of IND Application to Initiate Clinical Trial of DYNE-251 for Duchenne Muscular Dystrophy